Search research articles
Contact Us
Filters
Showing results (141-150 of 218) with videos related to
Page
of 22
Sort By:
The British Journal of Dermatology
|
December 11, 2008
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial
P C M van de Kerkhof, V Hoffmann, A Anstey, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
K Reich, U Mrowietz, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 22, 2016
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K Reich, M Gooderham, L Green, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 27, 2013
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis
U Mrowietz, E M G J de Jong, K Kragballe, et al.
Deutsche Medizinische Wochenschrift (1946)
|
October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]
U Müller-Ladner, R Alten, A Heiligenhaus, et al.
The British Journal of Dermatology
|
March 17, 2017
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)
K Reich, I Zschocke, H Bachelez, et al.
The British Journal of Dermatology
|
June 22, 2018
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
R B Warren, K Reich, R G Langley, et al.
International Archives of Occupational and Environmental Health
|
September 28, 2000
Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization
G A Westphal, A Schnuch, T G Schulz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 12, 2017
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study
A Blauvelt, K Reich, S Mehlis, et al.
Journal of the American Veterinary Medical Association
|
July 22, 2023
An avian Modified Glasgow Coma Scale as a prognostic indicator in raptors with head trauma
Kari D Foss, Krista A Keller, Sarah K Reich, et al.
Page
of 22
Search research articles
Search
Showing results (141-150 of 218) with videos related to
Sort By:
Page
of 22
The British Journal of Dermatology
|
December 11, 2008
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial
P C M van de Kerkhof, V Hoffmann, A Anstey, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
July 13, 2021
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
K Reich, U Mrowietz, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
October 22, 2016
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
K Reich, M Gooderham, L Green, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 27, 2013
A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis
U Mrowietz, E M G J de Jong, K Kragballe, et al.
Deutsche Medizinische Wochenschrift (1946)
|
October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]
U Müller-Ladner, R Alten, A Heiligenhaus, et al.
The British Journal of Dermatology
|
March 17, 2017
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)
K Reich, I Zschocke, H Bachelez, et al.
The British Journal of Dermatology
|
June 22, 2018
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database
R B Warren, K Reich, R G Langley, et al.
International Archives of Occupational and Environmental Health
|
September 28, 2000
Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization
G A Westphal, A Schnuch, T G Schulz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 12, 2017
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study
A Blauvelt, K Reich, S Mehlis, et al.
Journal of the American Veterinary Medical Association
|
July 22, 2023
An avian Modified Glasgow Coma Scale as a prognostic indicator in raptors with head trauma
Kari D Foss, Krista A Keller, Sarah K Reich, et al.
Page
of 22